Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Stepping Up to Health · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Stepping Up to Health only |
| 2 | EXPERIMENTAL | Stepping up to Health PLUS online message boards to talk with other participants |
| Name | Type | Description |
|---|---|---|
| Stepping Up to Health | BEHAVIORAL | Internet-mediated walking program with pedometers, goal-setting and tailored messaging |
Inclusion Criteria: * Must have one or more of the following: Coronary artery disease (CAD); BMI 25 or higher; Type 2 diabetes * Must be sedentary, defined by less than 150 minutes of self-reported activity per week * Must be 18 or older * Must have access to a computer with an Internet connection,...
Top 20 of 31 competitors
Stepping Up to Health is an investigational intervention being studied for use in Type 2 Diabetes. It is also being evaluated in patients with Coronary Artery Disease and Obesity. The intervention is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Stepping Up to Health is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker symbol JNJ. The company is conducting clinical research on this investigational intervention for Type 2 Diabetes and related conditions.
Stepping Up to Health is in Phase 1 clinical development. It is an investigational intervention and remains in clinical trials. It has not been approved by the FDA or any other regulatory agency for commercial use.
Stepping Up to Health has one completed clinical trial registered as NCT00729040, titled "Enhancing Adherence by Building Online Communities." This Phase 1 trial enrolled 324 participants with Type 2 Diabetes, Coronary Artery Disease, and Obesity. The trial was active-controlled and randomized.
Stepping Up to Health is not FDA approved. It is an investigational intervention currently in Phase 1 clinical development. The completed trial NCT00729040 was a Phase 1 study, and the intervention has not yet demonstrated sufficient evidence for regulatory approval.